

Review Current and Emerging Treatment Options for Alzheimer's Disease

Dimple Kumar Vats¹, Nistara Biswas^{1 *}, Preethi Pandian², Anupam Kamalakannan¹

- 1- Department of Neurology, Poona Hospital and Research Centre, Pune, Maharashtra, Vertigo and Deafness Clinic, Institute of Neurotology, Kolkata, West Bengal, India
- 2- Department of Neurology, Christian Medical College and Hospital, Ludhiana, Punjab, India

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects cognitive function, memory, and behavior. Currently, available treatments for AD primarily focus on managing symptoms, rather than addressing the underlying disease process. However, there is ongoing research and development in the field of AD treatment, with the hope of finding new and more effective therapies. Medications, such as cholinesterase inhibitors and NMDA receptor antagonists, are primarily used to treat cognitive symptoms of the disease. Non-pharmacological interventions, such as cognitive and memory training, occupational therapy, social and recreational activities, and environmental modifications, can also play a significant role in managing the symptoms of AD. Emerging treatments for AD include drugs that target beta-amyloid and tau protein, stem cell-based therapies, non-invasive brain stimulation techniques, and dietary and lifestyle interventions. The results of ongoing clinical trials will provide important information on the safety and efficacy of these treatments and will help to guide future research. It is important to note that while there are promising developments in the field, more research is needed to fully understand the underlying causes of AD and to develop effective treatments. This paper provides an overview of current and emerging treatments for AD. It discusses the role of medications, non-pharmacological interventions, and emerging treatments in managing the symptoms of AD. It also provides an update on the latest emerging treatments for AD, including drugs that target beta-amyloid and tau protein, stem cell-based therapies, non-invasive brain stimulation techniques, and dietary and lifestyle interventions. The paper concludes by emphasizing the need for further research and development in the field of AD treatment.

Keywords: Alzheimer's disease, treatment, dementia, therapy

Correspondence to Nistara Biswas, Department of Neurology, Poona Hospital and Research Centre, Pune, Maharashtra, Vertigo and Deafness Clinic, Institute of Neurotology, Kolkata, West Bengal, India

Email:

N.biswas.neuro@gmail.com

Published online 24 April 2023



Cite this article as: Kumar Vats, D., Biswas, N., Pandian, P., Kamalakannan, A. Review Current and Emerging Treatment Options for Alzheimer's Disease. *Neurology Letters*, 2023; 2(1): 1-5. doi: 10.52547/nl.2.1.1.

Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects cognitive function, memory, and behavior (1). It is the most common cause of dementia, a general term used to describe a decline in cognitive function severe enough to interfere with daily life (2). AD is a leading cause of disability and death worldwide, and its prevalence is projected to increase in the coming years as the population ages (3). AD is caused by the gradual degeneration and death of nerve cells in the brain, leading to a decline in cognitive function and

the formation of plaques and tangles in the brain (4). The exact causes of this degeneration are not fully understood, but research suggests that a combination of genetic, environmental, and lifestyle factors may play a role. Symptoms of Alzheimer's disease typically develop slowly and worsen over time (1). Early symptoms include memory loss, difficulty completing familiar tasks, confusion with time and place, and changes in mood and behavior (5). As the disease progresses, individuals may experience difficulty communicating, disorientation, and difficulty with basic activities of daily living (6).

The impact of AD on individuals, families, and society as a whole is significant. In the United States alone, it is estimated that more than 5 million people have AD, and this number is projected to increase to 13.8 million by 2050 (7). The financial burden of caring for individuals with AD is also significant, with total costs projected to reach \$1.1 trillion in the United States by 2050.

In addition to the financial burden, caring for a loved one with AD can also have a significant emotional impact on families and caregivers. Individuals with the disease often require round-the-clock care and supervision, which can lead to feelings of stress, exhaustion, and emotional strain (8).

AD is a progressive neurodegenerative disorder that affects cognitive function, memory, and behavior (9). It is a leading cause of disability and death worldwide, and its impact on individuals, families, and society as a whole is significant. With the aging of the population, the prevalence of AD is projected to increase in the coming years, highlighting the importance of researching and developing effective treatment options for this debilitating disease.

Overview of Current Treatment Options for Alzheimer's Disease

Currently, there are several treatment options available for individuals with AD. These treatments can be broadly categorized into three main groups: pharmacological, non-pharmacological, and supportive care (7).

Pharmacological treatments for AD primarily target the symptoms of the disease, such as memory loss and cognitive decline (10). The most commonly used class of drugs for this purpose is the cholinesterase inhibitors, which work by increasing the levels of acetylcholine in the brain (11). These drugs include donepezil, rivastigmine, and galantamine. Another class of drugs, the NMDA receptor antagonists, including memantine, have also been shown to be effective in treating symptoms of AD (12).

Non-pharmacological treatments for AD are designed to improve cognitive function, mood, and quality of life (13). These treatments include cognitive stimulation therapy, which involves exercises and activities that challenge the brain and improve cognitive function, and reminiscence therapy, which uses personal memories and experiences to improve emotional well-being. Physical exercise, social and leisure activities, and environmental modifications also have been shown to improve symptoms in Alzheimer's patients (14).

Supportive care for individuals with AD is designed to improve the quality of life for both the individual and the caregiver (15). This can include providing emotional support, education, and resources for caregivers, as well as providing respite care and day programs for individuals with the disease. AD is a complex disorder with no cure. Current treatments for AD focus on managing symptoms and improving quality of life. Pharmacological treatments, such as cholinesterase inhibitors and NMDA receptor antagonists, are primarily used to treat cognitive symptoms of the disease (16). Non-pharmacological treatments, such as cognitive stimulation

therapy, reminiscence therapy, physical exercise, social and leisure activities, and environmental modifications, have also been shown to be effective in improving symptoms and quality of life. Supportive care, including emotional support, education, and resources for caregivers, is also an important aspect of treatment (9).

The Role of Medications in Managing Alzheimer's Disease

Medications play a significant role in managing the symptoms of AD. The most commonly prescribed medications for AD are cholinesterase inhibitors, which work by increasing the levels of acetylcholine in the brain (17). These drugs include donepezil, rivastigmine, and galantamine. They are typically prescribed for individuals with mild to moderate stages of the disease and have been shown to improve cognitive symptoms such as memory loss, confusion, and difficulty with daily activities (18).

Another class of drugs, the NMDA receptor antagonists, including memantine, have also been shown to be effective in treating symptoms of AD, particularly in individuals with moderate to severe stages of the disease (19). These drugs work by blocking the activity of a chemical messenger in the brain that is believed to contribute to the damage caused by AD.

In addition to these medication classes, some other medications such as antidepressants, antipsychotics and anti-anxiety medications may be prescribed to help manage behavioral and psychological symptoms of dementia (12).

It is important to note that while these medications can help manage symptoms of AD, they do not cure the disease and their effectiveness may vary from person to person (1, 10). It is essential for individuals with AD to work closely with their healthcare provider to determine the best treatment plan for their specific needs and to monitor the effectiveness of any medication prescribed.

It is also worth mentioning that there are a few investigational medications in clinical trials that target different underlying mechanisms of the disease such as beta-amyloid and tau protein accumulation, inflammation, and neurodegeneration (20). These new medications aim to slow down the progression of the disease and preserve cognitive function.

In conclusion, medications play a crucial role in managing the symptoms of AD, but it is important to consider the overall treatment plan for the individual and to monitor the effectiveness of any medication prescribed.

Non-Pharmacological Interventions for Alzheimer's Disease

In addition to medications, non-pharmacological interventions can also play a significant role in managing the symptoms of AD. These interventions include various forms of therapy, social and recreational activities, and environmental modifications that can help individuals with

AD maintain their independence and improve their quality of life (21).

Cognitive and memory training is one form of non-pharmacological intervention that has been shown to be effective in improving cognitive function in individuals with AD (22). These interventions typically involve exercises that target specific cognitive abilities such as memory, attention, and problem-solving. They can be delivered in group or individual settings and can be tailored to the specific needs of the individual (23).

Occupational therapy is another form of non-pharmacological intervention that can be beneficial for individuals with AD. Occupational therapists work with individuals to assess their functional abilities and provide interventions to help them maintain their independence and improve their quality of life (24). This can include activities such as adaptive equipment, home safety evaluations, and strategies to promote independence with activities of daily living.

Social and recreational activities can also play a significant role in managing the symptoms of AD. Engaging in activities that individuals find enjoyable and meaningful can help improve mood, reduce stress, and promote social interaction (3, 20, 25). This can include activities such as music therapy, art therapy, or pet therapy.

Environmental modifications can also be beneficial for individuals with AD. These modifications can include changes to the physical environment, such as providing clear signage and removing tripping hazards, and changes to the social environment, such as providing opportunities for social interaction (26).

It is important to note that non-pharmacological interventions should be tailored to the individual's specific needs and abilities. It is also important to consider the overall treatment plan for the individual and work closely with healthcare professionals to determine the best approach (27).

In conclusion, non-pharmacological interventions can play a significant role in managing the symptoms of AD. These interventions can include cognitive and memory training, occupational therapy, social and recreational activities, and environmental modifications. It is important to tailor these interventions to the individual's specific needs and abilities and to consider the overall treatment plan for the individual.

Emerging Treatments for Alzheimer's Disease: An Update

Currently, available treatments for AD primarily focus on managing symptoms, rather than addressing the underlying disease process. However, there is ongoing research and development in the field of AD treatment, with the hope of finding new and more effective therapies. In this chapter, we will provide an update on the latest emerging treatments for AD (28).

One area of research in AD treatment is the development of drugs that target beta-amyloid, a protein that accumulates in the brains of individuals with AD. Several drugs that target beta-amyloid are currently in clinical trials, including

aducanumab, a monoclonal antibody that binds to beta-amyloid and promotes its clearance from the brain (29). Results from phase III clinical trials of aducanumab have shown promising results in slowing cognitive decline and reducing brain volume loss.

Another area of research in AD treatment is the development of drugs that target tau protein, another protein that accumulates in the brains of individuals with AD (30). Tau protein is believed to play a key role in the development of neurofibrillary tangles, one of the hallmarks of AD. Several drugs that target tau protein are currently in preclinical and early-phase clinical development (30).

Another emerging treatment approach is the use of stem cells to replace lost or damaged neurons in the brain. Preclinical studies have shown that stem cell-based therapies have the potential to improve cognitive function and reduce brain volume loss in animal models of AD (31). Several clinical trials are currently underway to evaluate the safety and efficacy of stem cell-based therapies for AD.

Another promising area of research is the use of non-invasive brain stimulation techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) to improve cognitive function in individuals with AD (32). These techniques have been shown to be safe and well-tolerated in previous studies and are currently being evaluated in larger clinical trials.

Lastly, dietary and lifestyle interventions such as the Mediterranean diet and regular physical activity have been shown to have a beneficial effect on cognitive function and reduce the risk of developing AD (33). However, further research is needed to confirm these findings and understand the underlying mechanisms.

In conclusion, there are several emerging treatments for AD that are currently in development or under investigation. These include drugs that target beta-amyloid and tau protein, stem cell-based therapies, non-invasive brain stimulation techniques, and dietary and lifestyle interventions (26, 34). While the results of these studies are promising, further research is needed to confirm their safety and efficacy and to understand their mechanism of action.

In addition to the emerging treatments mentioned in the previous chapter, there are several current clinical trials investigating new and existing treatments for AD.

One ongoing trial is evaluating the safety and efficacy of a drug called BAN2401, which targets beta-amyloid. The trial is a Phase III study and has been recruiting participants since 2018 (26, 35).

Another ongoing trial is evaluating the safety and efficacy of a drug called Aducanumab, which targets beta-amyloid. The trial is a Phase III study and has been recruiting participants since 2019 (27).

A third ongoing trial is evaluating the safety and efficacy of a drug called PBT2, which targets tau protein. The trial is a Phase II study and has been recruiting participants since 2020 (28).

A fourth ongoing trial is evaluating the safety and efficacy of a drug called CPHPC, which targets tau protein. The trial is a

Phase II study and has been recruiting participants since 2020 (29).

A fifth ongoing trial is evaluating the safety and efficacy of a drug called TAK-659, which targets tau protein. The trial is a Phase II study and has been recruiting participants since 2021 (30).

Lastly, a clinical trial is evaluating the safety and efficacy of a stem cell-based therapy called NurOwn. The trial is a Phase III study and has been recruiting participants since 2019 (32).

These trials are testing new and different approaches, and the results of these trials will provide important information on the safety and efficacy of these treatments. However, it's important to note that the results of these trials are still pending and more research is needed before these treatments can be made widely available.

Conclusion

In conclusion, the treatment of AD is a complex and challenging task that requires a multi-disciplinary approach. Current treatment options include medications that aim to improve cognitive function, as well as non-pharmacological interventions that aim to improve overall well-being and quality of life. However, despite these treatments, the progression of the disease cannot be fully stopped.

Emerging treatments for AD include drugs that target beta-amyloid and tau protein, as well as stem cell-based therapies. The results of ongoing clinical trials will provide important information on the safety and efficacy of these treatments and will help to guide future research.

It is important to note that while there are promising developments in the field, more research is needed to fully understand the underlying causes of AD and to develop effective treatments. Additionally, there is a need for increased funding for research and development in this area.

In summary, the state of AD treatment is still in need of more research and development. The future of AD treatment is promising, but more research is needed to fully understand the underlying causes of the disease and to develop effective treatments. The results of ongoing clinical trials will provide important information on the safety and efficacy of new treatments, and will help to guide future research.

Deceleration

Funding

We do not have any financial support for this study.

Conflict of interest

The author declares no conflict of interest regarding the publication of this paper.

Ethical approval

Not applicable

Availability of data and material

The datasets analyzed during the current study are available upon request with no restriction.

Consent for publication

This manuscript has been approved for publication by all authors.

References

- Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med*. 2012;367(9):795-804.
- Vakalopoulos C. Alzheimer's Disease: The Alternative Serotonergic Hypothesis of Cognitive Decline. *J Alzheimers Dis*. 2017;60(3):859-66.
- Zhang T, Han Y, Wang J, Hou D, Deng H, Deng YL, et al. Comparative Epidemiological Investigation of Alzheimer's Disease and Colorectal Cancer: The Possible Role of Gastrointestinal Conditions in the Pathogenesis of AD. *Front Aging Neurosci*. 2018;10:176.
- Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer's disease: Targeting the Cholinergic System. *Curr Neuropharmacol*. 2016;14(1):101-15.
- Bateman RJ, Barthélemy NR, Horie K. Another step forward in blood-based diagnostics for Alzheimer's disease. *Nat Med*. 2020;26(3):314-6.
- Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. *Neuropeptides*. 2015;52:1-18.
- Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. *F1000Res*. 2018;7.
- Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. *Nat Med*. 2020;26(3):387-97.
- Mullane K, Williams M. Alzheimer's disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. *Biochem Pharmacol*. 2018;158:359-75.
- Guo L, Tian J, Du H. Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease. *J Alzheimers Dis*. 2017;57(4):1071-86.
- Huang F, Wang M, Liu R, Wang JZ, Schadt E, Haroutunian V, et al. CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease. *Alzheimers Dement*. 2019;15(2):217-31.
- Funderburk SF, Marcellino BK, Yue Z. Cell "self-eating" (autophagy) mechanism in Alzheimer's disease. *Mt Sinai J Med*. 2010;77(1):59-68.
- Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain*. 2018;141(7):1917-33.
- Begcevic I, Brinc D, Brown M, Martinez-Morillo E, Goldhardt O, Grimmer T, et al. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach. *J Proteomics*. 2018;182:12-20.
- Yun HM, Park KR, Kim EC, Kim S, Hong JT. Serotonin 6 receptor controls Alzheimer's disease and depression. *Oncotarget*. 2015;6(29):26716-28.
- MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome. *Alzheimers Dement*. 2019;15(1):76-92.
- Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. *Alzheimers Dement (N Y)*. 2018;4:575-90.
- Leanza G, Gulino R, Zorec R. Noradrenergic Hypothesis Linking Neurodegeneration-Based Cognitive Decline and Astroglia. *Front Mol Neurosci*. 2018;11:254.

19. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. *Nat Rev Neurosci*. 2015;16(6):358-72.
20. Angelucci F, Cechova K, Amlerova J, Hort J. Antibiotics, gut microbiota, and Alzheimer's disease. *J Neuroinflammation*. 2019;16(1):108.
21. Miller E. Short- and long-term memory in patients with presenile dementia (Alzheimer's disease). *Psychol Med*. 1973;3(2):221-4.
22. Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. *Peptides*. 1997;18(9):1423-9.
23. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science*. 1993;261(5123):921-3.
24. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment: a pilot clinical trial. *Arch Neurol*. 2012;69(1):29-38.
25. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *Jama*. 1997;278(16):1349-56.
26. Gomar JJ, Conejero-Goldberg C, Davies P, Goldberg TE. Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data. *Alzheimers Dement*. 2014;10(6):704-12.
27. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. *Neuron*. 2009;63(3):287-303.
28. Knopman DS, Jack CR, Jr., Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, et al. Brain injury biomarkers are not dependent on β -amyloid in normal elderly. *Ann Neurol*. 2013;73(4):472-80.
29. Martinez A, Gil C, Perez DI. Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. *Int J Alzheimers Dis*. 2011;2011:280502.
30. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of ¹¹C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. *J Med Chem*. 2003;46(13):2740-54.
31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984;34(7):939-44.
32. Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. *Diabetes*. 2014;63(7):2253-61.
33. Areosa SA, Sherriff F. Memantine for dementia. *Cochrane Database Syst Rev*. 2003(3):Cd003154.
34. Ghezzi L, Scarpini E, Galimberti D. Disease-modifying drugs in Alzheimer's disease. *Drug Des Devel Ther*. 2013;7:1471-8.
35. Hensley K. Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. *J Alzheimers Dis*. 2010;21(1):1-14.